Breast Cancer

Sheila Ridner, PhD, RN, FAAN, discusses the implications of the PREVENT study and how oncology nurses can advocate for patients with breast cancer.

New data demonstrate that regular exercise can help patients with breast cancer mitigate the physical and mental treatment–related side effects that might impact their quality of life.

Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.

Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.

The PARP inhibitor demonstrated impressive overall survival benefit in patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.

La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.

Sheila L. Ridner, PhD, RN, FAAN, provides an overview of bioimpedance spectroscopy and how the simple design allows for standardized subclinical lymphedema surveillance in breast cancer survivors.

Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.

Olaparib is now FDA approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer and who have already undergone chemotherapy before or after surgery.

New data support the use of ribociclib plus letrozole in the treatment of patients with postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Lindsay Kroener, MD, offers an overview of current fertility preservation options for patients about to undergo cancer therapy.

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.

Patients with HER2-negative, locally advanced or metastatic breast cancer have experienced improved survival rates both in real-world data and the phase 3 EMBRACA trial.

Ahead of his presentation at the 39th Annual Miami Breast Cancer Conference, Charles L. Loprinzi, MD, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer.

At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.

Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.

Combination therapy, selective estrogen receptor degraders, and more were covered at the 2021 San Antonio Breast Cancer Symposium.

Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.

The update is in agreement with the FDA approval of a labeling supplement in June 2021 to the United States Prescribing Information for neratinib in HER2-positive breast cancer.

A supplemental biologics license application has been granted to trastuzumab deruxtecan-nxki for the treatment of adult patients with select HER2-positive breast cancer.

A patient-reported outcome survey highlighted quality-of-life gaps in breast cancer survivorship.

An expert discusses the implications of a subgroup analysis of the DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer.

Compared with other antibody-drug conjugates, datopotamab deruxtecan was associated with lower rates of neutropenia, pneumonitis, and hematologic toxicity.